Cholangiocarcinoma Foundation
Cholangiocarcinoma Foundation shows strong growth and zero reported officer compensation over a decade.
EIN: 205776861 · Salt Lake City, UT · NTEE: H99 · Updated: 2026-03-28
| Metric | Value |
|---|---|
| Total Revenue | $7.2M |
| Total Expenses | $5.3M |
| Program Spending | 85% |
| Net Assets | $3.6M |
| Transparency Score | 90/100 |
Is Cholangiocarcinoma Foundation Legit?
Some Concerns
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
Cholangiocarcinoma Foundation directs 85% of its spending to programs. This exceeds the industry benchmark of 65%, indicating strong mission focus.
About Cholangiocarcinoma Foundation
Cholangiocarcinoma Foundation (EIN: 205776861) is a nonprofit organization based in Salt Lake City, UT, classified under NTEE code H99. The organization reported total revenue of $7.2M and total assets of $5.8M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Cholangiocarcinoma Foundation's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
Organization Overview
Cholangiocarcinoma Foundation is a mid-size nonprofit that has been operating for 19 years, with 12 years of IRS 990 filings on record (2011–2023). Revenue has grown at a compound annual rate of 33.0%.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
| Total Revenue | $5.1M |
| Total Expenses | $5.3M |
| Surplus / Deficit | $-183,377 |
| Total Assets | $4.6M |
| Total Liabilities | $993K |
| Net Assets | $3.6M |
| Operating Margin | -3.6% |
| Debt-to-Asset Ratio | 21.5% |
| Months of Reserves | 10.5 months |
Financial Health Grade: B
In 2023, Cholangiocarcinoma Foundation reported a deficit of $183K with expenses exceeding revenue, holds 10.5 months of operating reserves (strong position), has a debt-to-asset ratio of 21.5% (moderate leverage).
Financial Trends
Over 12 years of filings (2011–2023), Cholangiocarcinoma Foundation's revenue has grown at a compound annual growth rate (CAGR) of 33.0%.
| Year | Revenue Change | Expense Change | Asset Change |
|---|---|---|---|
| 2023 | +3.0% | +45.5% | +15.1% |
| 2022 | +26.5% | +58.8% | +46.4% |
| 2021 | +106.7% | +27.9% | +125.0% |
| 2020 | -14.6% | -7.8% | +49.5% |
| 2019 | +44.7% | +50.0% | +16.7% |
IRS Tax-Exempt Classification
| IRS Classification Codes | 1000 |
| IRS Ruling Date | 2007 |
Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.
AI Transparency Report
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Cholangiocarcinoma Foundation with a Mission Score of 90 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Spending Breakdown
- admin: 10%
- programs: 85%
- fundraising: 5%
According to IRS 990 filings, Cholangiocarcinoma Foundation allocates its expenses as follows: admin: 10%, programs: 85%, fundraising: 5%. With 85% directed toward programs, this reflects a strong commitment to its charitable mission.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
- The organization reported a deficit of $183K, with expenses exceeding revenue.
- Debt-to-asset ratio: 21.5%.
Executive Compensation Analysis
The Cholangiocarcinoma Foundation consistently reports 0% officer compensation across all available filings, which is highly unusual for an organization of its size and growth, suggesting either pro-bono leadership or compensation is categorized differently, warranting further investigation for complete transparency.
Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.
Red Flags
The following concerns were identified during AI analysis of Cholangiocarcinoma Foundation's IRS 990 filings:
- Expenses slightly exceeded revenue in the 202306 period ($5,266,027 vs. $5,082,650), which is a deviation from prior years' surpluses.
- Consistent 0% officer compensation reported across all filings for an organization of this size and growth is unusual and might warrant further inquiry into how leadership is compensated or if it's entirely volunteer-driven.
Strengths
The following positive indicators were identified for Cholangiocarcinoma Foundation:
- Exceptional revenue growth from $326,189 in 2013 to $5,082,650 in 2023, demonstrating increasing support.
- Strong asset growth from $254,097 in 2013 to $4,624,165 in 2023, indicating financial stability and capacity.
- Consistently reported 0% officer compensation across all filings, suggesting a high dedication to mission and efficient use of funds.
- Generally healthy financial surpluses in most years, indicating sound financial management.
- Low liabilities relative to assets in most periods, reflecting good financial health.
Frequently Asked Questions about Cholangiocarcinoma Foundation
Is Cholangiocarcinoma Foundation a legitimate charity?
Based on AI analysis of IRS 990 filings, Cholangiocarcinoma Foundation (EIN: 205776861) some concerns. Mission Score: 90/100. 2 red flags identified, 5 strengths noted.
How does Cholangiocarcinoma Foundation spend its money?
Cholangiocarcinoma Foundation directs 85% of its spending to programs and services. The remaining budget covers administration and fundraising costs.
Are donations to Cholangiocarcinoma Foundation tax-deductible?
Cholangiocarcinoma Foundation is registered as a tax-exempt nonprofit (EIN: 205776861). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
What percentage of Cholangiocarcinoma Foundation's spending goes to programs?
Cholangiocarcinoma Foundation directs 85% to programs, 5% to fundraising. This exceeds the 65% industry benchmark for efficient nonprofits.
How does Cholangiocarcinoma Foundation compare to similar nonprofits?
With a transparency score of 90/100 (Excellent), Cholangiocarcinoma Foundation is above average for NTEE category H99 nonprofits. The score reflects financial transparency, program spending efficiency, and governance quality based on IRS 990 data.
Where is Cholangiocarcinoma Foundation located?
Cholangiocarcinoma Foundation is headquartered in Salt Lake City, Utah and files with the IRS under EIN 205776861. It is classified under NTEE code H99.
How many years of IRS 990 filings does Cholangiocarcinoma Foundation have?
Cholangiocarcinoma Foundation has 12 years of IRS 990 filings on record at NonprofitSpending. This extensive filing history provides a strong basis for evaluating long-term financial trends. The most recent filing shows $7.2M in total revenue.
Is Cholangiocarcinoma Foundation a good charity?
Based on its consistent growth in revenue and assets, and the reported 0% officer compensation, the Cholangiocarcinoma Foundation appears to be a very good charity, demonstrating strong financial health and a clear dedication to its mission.
How has the organization's financial health changed over time?
The organization has experienced significant financial growth, with revenue increasing from $326,189 in 2013 to $5,082,650 in 2023, and assets growing from $254,097 to $4,624,165 over the same period, indicating robust expansion and financial stability.
What is the trend in expenses versus revenue?
Generally, the organization has maintained healthy surpluses, with revenue exceeding expenses in most years (e.g., 2022 revenue of $4,935,665 vs. expenses of $3,620,452). The 2023 filing shows expenses ($5,266,027) slightly exceeding revenue ($5,082,650), which could be an investment year or a temporary fluctuation.
Filing History
IRS 990 filing history for Cholangiocarcinoma Foundation showing financial trends over 12 years of public records:
Over 12 years of IRS 990 filings (2011–2023), Cholangiocarcinoma Foundation's revenue has grown by 2956%, moving from $166K to $5.1M. Total assets increased by 2390.6% over the same period, from $186K to $4.6M. Total functional expenses rose by 3940.3%, from $130K to $5.3M. In its most recent filing year (2023), Cholangiocarcinoma Foundation reported a deficit of $183K, with expenses exceeding revenue. The organization holds $993K in liabilities against $4.6M in assets (debt-to-asset ratio: 21.5%), resulting in net assets of $3.6M.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. % | |
|---|---|---|---|---|---|---|
| 2023 | $5.1M | $5.3M | $4.6M | $993K | — | View 990 |
| 2022 | $4.9M | $3.6M | $4.0M | $265K | — | View 990 |
| 2021 | $3.9M | $2.3M | $2.7M | $306K | — | View 990 |
| 2020 | $1.9M | $1.8M | $1.2M | $405K | — | View 990 |
| 2019 | $2.2M | $1.9M | $816K | $106K | — | View 990 |
| 2018 | $1.5M | $1.3M | $699K | $267K | — | View 990 |
| 2016 | $904K | $924K | $394K | $66K | — | View 990 |
| 2015 | $841K | $778K | $423K | $79K | — | View 990 |
| 2014 | $561K | $529K | $310K | $29K | — | View 990 |
| 2013 | $326K | $245K | $254K | $6K | — | View 990 |
| 2012 | $250K | $269K | $167K | $374 | — | View 990 |
| 2011 | $166K | $130K | $186K | $208 | — | View 990 |
Year-by-Year Financial Summary
- 2023: Revenue of $5.1M, expenses of $5.3M, and assets of $4.6M (revenue +3.0% year-over-year).
- 2022: Revenue of $4.9M, expenses of $3.6M, and assets of $4.0M (revenue +26.5% year-over-year).
- 2021: Revenue of $3.9M, expenses of $2.3M, and assets of $2.7M (revenue +106.7% year-over-year).
- 2020: Revenue of $1.9M, expenses of $1.8M, and assets of $1.2M (revenue -14.6% year-over-year).
- 2019: Revenue of $2.2M, expenses of $1.9M, and assets of $816K (revenue +44.7% year-over-year).
- 2018: Revenue of $1.5M, expenses of $1.3M, and assets of $699K (revenue +68.9% year-over-year).
- 2016: Revenue of $904K, expenses of $924K, and assets of $394K (revenue +7.5% year-over-year).
- 2015: Revenue of $841K, expenses of $778K, and assets of $423K (revenue +49.9% year-over-year).
- 2014: Revenue of $561K, expenses of $529K, and assets of $310K (revenue +72.1% year-over-year).
- 2013: Revenue of $326K, expenses of $245K, and assets of $254K (revenue +30.6% year-over-year).
- 2012: Revenue of $250K, expenses of $269K, and assets of $167K (revenue +50.2% year-over-year).
- 2011: Revenue of $166K, expenses of $130K, and assets of $186K.
View Individual Filing Years
Explore detailed financial data from each IRS 990 filing year for Cholangiocarcinoma Foundation:
Data Sources and Methodology
This transparency report for Cholangiocarcinoma Foundation is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.